Payers subject 80% of new RA and MS patients to utilization management restrictions

A newanalysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine encountered a utilization management restriction. Of those patients, 3 out of 10 were unable to gain approval from their commercial market health plan to start new treatments their doctors prescribed for them within 30 days.

Source: The Catalyst - July 22, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Out-of-Pocket Costs Let's Talk About Cost Source Type: news